¼¿ï´ëÇб³¾î¸°À̺´¿ø ´ëÇѺÎÀÎÁ¾¾çÇÐȸ Chemo-TIP Review Course 2020: Gynecologic Cancer : 2020-02-08±³À°ÀÏÀÚ : 2020-02-08
±³À°Àå¼Ò : ¼¿ï´ëÇб³¾î¸°À̺´¿ø ÀÓ»ó °ÀǽÇ
±³À°ÁÖÁ¦ :
Chemo-TIP Review Course 2020: Gynecologic CancerÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
´ã´çÀÚ : ÇѼ¼¹Ì
¿¬¶ôó : 02-512-0044
À̸ÞÀÏ :
office@sgo.or.kr ±³À°Á¾·ù : »êºÎÀΰú
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 35ºÐ
¼¼ºÎ¼ö°·á : 80,000¿ø
ºñ°í Àü¹®ÀÇ 80,000 / Àü°øÀÇ,¾Ë¹ÝÀÇ 60,000 / ¿¬±¸¿ø, °£È£»ç 40,000 / ¸¸ 65¼¼ÀÌ»ó, ÁÂÀå, ¿¬ÀÚ ¹«·á
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 02-08 ¼¿ï´ëÇб³¾î¸°À̺´¿ø ÀÓ»ó °ÀÇ½Ç 08:30~08:50 Registration ()
±âŸ 02-08 ¼¿ï´ëÇб³¾î¸°À̺´¿ø ÀÓ»ó °ÀÇ½Ç 08:50~09:00 °³È¸»ç ±è½Âö(´ëÇѺÎÀÎÁ¾¾çÇÐȸ ȸÀå)
±³À°½Ã°£ 02-08 ¼¿ï´ëÇб³¾î¸°À̺´¿ø ÀÓ»ó °ÀÇ½Ç 09:00~09:20 Cervix cancer ±è¹Ì¼±(Â÷ÀÇ´ë)
±³À°½Ã°£ 02-08 ¼¿ï´ëÇб³¾î¸°À̺´¿ø ÀÓ»ó °ÀÇ½Ç 09:20~09:40 Uterine cancer À̼ºÁ¾(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 02-08 ¼¿ï´ëÇб³¾î¸°À̺´¿ø ÀÓ»ó °ÀÇ½Ç 09:40~10:00 Ovarian cancer ¹éÀ̼±(¼º±Õ°üÀÇ´ë)
Åä·Ð 02-08 ¼¿ï´ëÇб³¾î¸°À̺´¿ø ÀÓ»ó °ÀÇ½Ç 10:00~10:15 Discussion ()
ÈÞ½Ä 02-08 ¼¿ï´ëÇб³¾î¸°À̺´¿ø ÀÓ»ó °ÀÇ½Ç 10:15~10:35 COFFEE BREAK ()
±³À°½Ã°£ 02-08 ¼¿ï´ëÇб³¾î¸°À̺´¿ø ÀÓ»ó °ÀÇ½Ç 10:35~10:50 Special topic 1: SOLO1 & SOLO2 À̽¹Ì(°è¸íÀÇ´ë)
±³À°½Ã°£ 02-08 ¼¿ï´ëÇб³¾î¸°À̺´¿ø ÀÓ»ó °ÀÇ½Ç 10:50~11:10 Targeted agents ÀÌÁ¤À±(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 02-08 ¼¿ï´ëÇб³¾î¸°À̺´¿ø ÀÓ»ó °ÀÇ½Ç 11:10~11:30 PARP inhibitors ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 02-08 ¼¿ï´ëÇб³¾î¸°À̺´¿ø ÀÓ»ó °ÀÇ½Ç 11:30~11:50 Immuno-oncologics ÃÖÀ±Áø(°¡Å縯ÀÇ´ë)
Åä·Ð 02-08 ¼¿ï´ëÇб³¾î¸°À̺´¿ø ÀÓ»ó °ÀÇ½Ç 11:50~12:00 Discussion ()
±³À°½Ã°£ 02-08 ¼¿ï´ëÇб³¾î¸°À̺´¿ø ÀÓ»ó °ÀÇ½Ç 12:00~12:15 Special topic 2: Patient blood management ÀÌÁ¤Àç(¼øõÇâÀÇ´ë)
½Ä»ç 02-08 ¼¿ï´ëÇб³¾î¸°À̺´¿ø ÀÓ»ó °ÀÇ½Ç 12:15~13:20 LUNCH ()
±³À°½Ã°£ 02-08 ¼¿ï´ëÇб³¾î¸°À̺´¿ø ÀÓ»ó °ÀÇ½Ç 13:20~13:40 Chemotherapy-induced peripheral neuropathy (CIPN) À̼øÅÂ(¼¿ïÀÇ´ë ½Å°æ°ú)
±³À°½Ã°£ 02-08 ¼¿ï´ëÇб³¾î¸°À̺´¿ø ÀÓ»ó °ÀÇ½Ç 13:40~14:00 Hematologic toxicity ÀÌÀºÁö(¼¿ïÀÇ´ë)
±³À°½Ã°£ 02-08 ¼¿ï´ëÇб³¾î¸°À̺´¿ø ÀÓ»ó °ÀÇ½Ç 14:00~14:20 Chemotherapy-induced nausea & vomiting (CINV) ¾î°æÁø(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 02-08 ¼¿ï´ëÇб³¾î¸°À̺´¿ø ÀÓ»ó °ÀÇ½Ç 14:20~14:40 Hypersensitivity & septic shock ±è¼¼ÀÍ(¼¿ïÀÇ´ë)
Åä·Ð 02-08 ¼¿ï´ëÇб³¾î¸°À̺´¿ø ÀÓ»ó °ÀÇ½Ç 14:40~14:50 Discussion ()
±³À°½Ã°£ 02-08 ¼¿ï´ëÇб³¾î¸°À̺´¿ø ÀÓ»ó °ÀÇ½Ç 14:50~15:10 Special topic 3: ½É»çÆò°¡¿øÀÇ Ç×¾ÏÄ¡·á ½É»ç °æÇâ ±è¿ë¹ü(¼¿ïÀÇ´ë)
Åä·Ð 02-08 ¼¿ï´ëÇб³¾î¸°À̺´¿ø ÀÓ»ó °ÀÇ½Ç 15:10~15:15 Discussion ()
±³À°½Ã°£ 02-08 ¼¿ï´ëÇб³¾î¸°À̺´¿ø ÀÓ»ó °ÀÇ½Ç 15:15~15:30 Special topic 4: Niraparib ±è¹Ì°æ(ÀÌÈÀÇ´ë)
ÈÞ½Ä 02-08 ¼¿ï´ëÇб³¾î¸°À̺´¿ø ÀÓ»ó °ÀÇ½Ç 15:30~15:50 COFFEE BREAK ()
±³À°½Ã°£ 02-08 ¼¿ï´ëÇб³¾î¸°À̺´¿ø ÀÓ»ó °ÀÇ½Ç 15:50~16:20 Cervical cancer À̸¶¸®¾Æ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 02-08 ¼¿ï´ëÇб³¾î¸°À̺´¿ø ÀÓ»ó °ÀÇ½Ç 16:20~16:50 Uterine cancer ½É½ÂÇõ(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 02-08 ¼¿ï´ëÇб³¾î¸°À̺´¿ø ÀÓ»ó °ÀÇ½Ç 16:50~17:20 Ovarian cancer ÀÌÀ¯¿µ(¼º±Õ°üÀÇ´ë)